Hoth Therapeutics, Inc. Soared
Hoth Therapeutics, Inc. (HOTH:NASDAQ) rocketted at $1.53, a gain of 66.4%. On Wed, Jun 04, 2025, HOTH:NASDAQ hit a New 2-Week High of $1.53. The stock appeared on our News Catalysts scanner on Mon, May 12, 2025 at 09:09 AM in the 'BIOTECH' category. From Wed, May 21, 2025, the stock recorded 66.67% Up Days and 50.00% Green Days
The stock spiked on Tue, Jan 07, 2025 at $3.8 with a volume of 417M+.
About Hoth Therapeutics, Inc. (HOTH:NASDAQ)
Hoth Therapeutics Inc is a development stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Top 10 Gainers:
- Smart for Life, Inc. (SMFL:NASDAQ), 225%
- K Wave Media Ltd. (KWM:NASDAQ), 133.33%
- Liminatus Pharma, Inc. (LIMN:NASDAQ), 132.78%
- Latch, Inc. (LTCH:NASDAQ), 75%
- Nano Labs Ltd (NA:NASDAQ), 71.24%
- Sharps Technology, Inc. (STSS:NASDAQ), 68.72%
- Lyell Immunopharma, Inc. (LYEL:NASDAQ), 68.59%
- Hoth Therapeutics, Inc. (HOTH:NASDAQ), 66.36%
- Cellectar Biosciences, Inc. (CLRB:NASDAQ), 66.32%
- mF International Limited (MFI:NASDAQ), 60.83%